Microangiopathy IN Diabetes
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
This clinical trial aims to evaluate the use of a contactless and non-invasive technique to measure the properties of the skin's microcirculation and its regulatory functions in both healthy individuals and patients with microvascular disease associated with type 1 diabetes. It is hoped that the study results will lead to the development of a useful method for detecting diabetic complications at an early stage, thereby enabling treatment and preventive measures before the onset of severe microangiopathy.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 60
Healthy Volunteers: t
View:
• Diabetes mellitus type 1.
• Cohort specific inclusion criteria apply, please review 'groups' section.
Locations
Other Locations
Sweden
Danderyd University Hospital
RECRUITING
Danderyd
Contact Information
Primary
Sara Tehrani, Medical Doctor
sara.tehrani@ki.se
+46 08 123 550 00
Backup
Jacob Widaeus, Medical Doctor
jacob.widaeus@ki.se
+46 08 123 596 01
Time Frame
Start Date: 2024-03-01
Estimated Completion Date: 2027-12
Participants
Target number of participants: 400
Treatments
Severe diabetic microangiopathy
Severe micro-angiopathy defined as proliferative retinopathy, macroalbuminuria, and kidney failure with at least CKD-class 3B and severe neuropathy with or without foot ulcers. Aged 18-60 years old.
Moderate diabetic microangiopathy
Moderate non-proliferative retinopathy or proliferative retinopathy, macroalbuminuria or kidney failure defined as estimated glomerular filtration rate \<60 mL/min/1.73 m2 body surface, and manifest neuropathy. Aged 18-45 years old.
Mild diabetic microangiopathy
Mild-moderate non-proliferative retinopathy and/or microalbuminuria and/or early signs of neuropathy. Aged 18-45 years old.
No diabetic microangiopathy
No microangiopathic complications, except for simplex or background retinopathy, which is an early and reversible state. Aged 18-45 years old.
Related Therapeutic Areas
Sponsors
Collaborators: Neko Health AB
Leads: Karolinska Institutet